ArticleCirculation research2013
Pegylation of high-density lipoprotein decreases plasma clearance and enhances antiatherogenic activity.
Article in Circulation research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 56 citations in OpenAlex.
- Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patients.British journal of clinical pharmacology · 2021Trial
- Inventive HDL Mimicking Nanoparticles: A Promising Frontier in Cardiovascular Disease Management.Cardiovascular toxicology · 2025Review
- Clinical Pharmacokinetics and Pharmacodynamics of CSL112.Clinical pharmacokinetics · 2023Review
- Biomembrane-Derived Nanoparticles in Alzheimer's Disease Therapy: A Comprehensive Review of Synthetic Lipid Nanoparticles and Natural Cell-Derived Vesicles.International journal of nanomedicine · 2023Review
- Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity.Journal of the American Heart Association · 2022Review
- Addressing dyslipidemic risk beyond LDL-cholesterol.The Journal of clinical investigation · 2022Review
- Effect of apoA-I PEGylation on the Biological Fate of Biomimetic High-Density Lipoproteins.ACS omega · 2021Article
- Nascent HDL (High-Density Lipoprotein) Discs Carry Cholesterol to HDL Spheres: Effects of HDL Particle Remodeling on Cholesterol Efflux.Arteriosclerosis, thrombosis, and vascular biology · 2020Article
- Nanotechnology Approaches in Tackling Cardiovascular Diseases.Molecules (Basel, Switzerland) · 2019Review
- Defective cholesterol metabolism in haematopoietic stem cells promotes monocyte-driven atherosclerosis in rheumatoid arthritis.European heart journal · 2018Article
- Effect of Synthetic High Density Lipoproteins Modification with Polyethylene Glycol on Pharmacokinetics and Pharmacodynamics.Molecular pharmaceutics · 2018Article
- Combating atherosclerosis with targeted nanomedicines: recent advances and future prospective.BioImpacts : BI · 2018Review
- Reconstituted high-density lipoproteins: novel biomimetic nanocarriers for drug delivery.Acta pharmaceutica Sinica. B · 2018Review
- Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting.Nanomedicine : nanotechnology, biology, and medicine · 2017Article
- Plaque-hyaluronidase-responsive high-density-lipoprotein-mimetic nanoparticles for multistage intimal-macrophage-targeted drug delivery and enhanced anti-atherosclerotic therapy.International journal of nanomedicine · 2017Article
- Deficiency of ATP-Binding Cassette Transporters A1 and G1 in Endothelial Cells Accelerates Atherosclerosis in Mice.Arteriosclerosis, thrombosis, and vascular biology · 2016Article
- High-density lipoprotein mimetics: promises and challenges.The Biochemical journal · 2015Review
- Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL.International journal of molecular sciences · 2015Review
- Cholesterol, inflammation and innate immunity.Nature reviews. Immunology · 2015 · on this mapReview
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
rationaleInfusions of apolipoprotein AI (apoAI), mimetic peptides, or high-density lipoprotein (HDL) remain a promising approach for the treatment of atherosclerotic coronary disease. However, rapid clearance leads to a requirement for repeated administration of large amounts of material and limits effective plasma concentrations.
objectiveBecause pegylation of purified proteins is commonly used as a method to increase their half-life in the circulation, we determined whether pegylation of apoAI or HDL would increase its plasma half-life and in turn its antiatherogenic potential. METHODS AND
resultsInitial pegylation attempts using lipid-poor apoAI showed a marked tendency to form multi-pegylated (PEG) species with reduced ability to promote cholesterol efflux from macrophage foam cells. However, pegylation of human holo-HDL or reconstituted phospholipid/apoAI particles (rHDL) led to selective N-terminal monopegylation of apoAI with full preservation of cholesterol efflux activity. The plasma clearance of PEG-rHDL was estimated after injection into hypercholesterolemic Apoe-/- mice; the half-life of pegylated PEG-apoAI after injection of PEG-rHDL was increased ≈7-fold compared with apoAI in nonpegylated rHDL. In comparison with nonpegylated rHDL, infusion of PEG-rHDL (40 mg/kg) into hypercholesterolemic Apoe-/- mice led to more pronounced suppression of bone marrow myeloid progenitor cell proliferation and monocytosis, as well as reduced atherosclerosis and a stable plaque phenotype.
conclusionsWe describe a novel method for effective monopegylation of apoAI in HDL particles, in which lipid binding seems to protect against pegylation of key functional residues. Pegylation of apoAI in rHDL markedly increases its plasma half-life and enhances antiatherogenic properties in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.